Industry Forecast: Antisense & RNAi Therapeutics Market to Generate $3.11 Billion Revenue by 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Outlook for the Antisense & RNAi Therapeutics Market Heading Into 2029?
In recent years, the antisense & RNAi therapeutics market has seen significant expansion. The market, valued at $1.75 billion in 2024, is expected to grow to $1.93 billion in 2025 with a compound annual growth rate (CAGR) of 10.2%. Several factors contribute to this growth during the historical period, including increased funding, advancements in technology, elevated healthcare spending, a quickly aging population, and economic growth in developing markets.
The market for antisense and RNAi therapeutics is projected to experience fast-paced expansion in the coming years, with expected growth to “$3.11 billion in 2029 at a compound annual growth rate (CAGR) of 12.8%.” This anticipated surge during the forecast period could be linked to enhanced healthcare accessibility, growing cancer prevalence and a spike in the requirement for antisense and RNAi therapeutics due to the COVID-19 pandemic. Key trends throughout this period look set to involve concentrated research and development efforts for RNA therapeutic treatments for rare diseases, the employment of nanoparticles, the creation of advanced and more effective antisense and RNAi therapeutics, and partnerships with other firms for product innovation and revenue generation.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp
Which Factors Are Pushing The Antisense & RNAi Therapeutics Market Forward?
The surging incidence of maladies such as coronary artery diseases, neurodegenerative disorders, and infectious diseases is predicted to spur the demand for the antisense & RNAi therapeutics market. Treatment strategies that suppress genes, such as RNA interference and antisense oligonucleotides, are employed to treat numerous neurodegenerative disorders by mending defective genes. For example, a report from the American Heart Association, an organization based in the US, stated that in January 2024, the age-adjusted mortality rate from cardiovascular diseases rose to 233.3 per 100,000, a 4.0% increase from the preceding year. Consequently, the rising incidence of multiple neurodegenerative and infectious diseases is anticipated to be a key driver of growth for the antisense & RNAi therapeutics market.
The antisense & rnai therapeutics market covered in this report is segmented –
1) By Technology: RNA Interference, Antisense RNA
2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications
Subsegments:
1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics
2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides
What Are The Leading Trends And Opportunities In The Antisense & RNAi Therapeutics Sector?
Leading businesses in the antisense & RNAi therapeutics market are employing strategic actions like collaborations and partnerships to maintain their competitiveness in the escalating market arena. Such a strategic partnership typically involves multiple firms cooperating to fulfil a shared goal or objective. For instance, in January 2023, Orbit Discovery Limited, a company from the US that provides services for peptide discovery, formed an alliance with SanegeneBio Inc., a UK-based firm developing innovative RNAi-based medicines. This partnership is geared towards developing advanced RNAi therapeutics, with a specific focus on identifying tissue-specific delivery of RNA therapeutics for more efficient gene knockdown. The partnership extends to hit identification and cell-based internalization research, with SanegeneBio having the choice to advance the development of the hits that come from the screening phases, using Orbit’s original rapid peptide lead discovering technology. Orbit Discovery’s one-of-a-kind peptide display system facilitates the screening of significant peptide libraries, resulting in faster identification of relevant peptide leads via affinity and functional screens.
Which Organizations Are Driving Progress In The Antisense & RNAi Therapeutics Industry?
Major companies operating in the antisense & RNAi therapeutics market include Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilaç ve Saglik Ürünleri A.S., Egypt Otsuka Pharmaceutical
Which Region Is Expected To Experience The Highest Growth In The Antisense & RNAi Therapeutics Industry?
North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=3389&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
